The thesis

Medpace is a contract research organization delivering clinical development services with 2876.0% gross margin and 17.2% YoY revenue growth. The company is in a risk-on rotation macro moment with a conviction score of 17/100. Analyst consensus is HOLD, but the company's high revenue growth and margins make it compelling. The P/E ratio is 35.6x, indicating potential valuation risk.

Why now

The risk-on rotation is underway, and Medpace's revenue growth is driven by the GLP-1 & Metabolic Health theme, which is gaining traction. The company's 17.2% YoY revenue growth makes it an attractive play in this theme.

What to watch

Medpace's next quarter revenue growth and any significant developments in the GLP-1 & Metabolic Health theme, such as new trial results or insurance coverage decisions. The company's ability to maintain its high gross margin of 2876.0% will also be a key indicator.

Key risks

Trial results and insurance coverage decisions can negatively impact Medpace's clients and subsequently the company's revenue. The high P/E ratio of 35.6x indicates valuation risk if revenue growth slows down.

Theme exposure